Pyridone compounds and methods of use in the modulation of a protein kinase
WO2020247418A1
Compounds for the treatment of kinase-dependent disorders
WO2020154610A1
Compounds for the treatment of kinase-dependent disorders
WO2020247019A1
Crystalline salt forms of a kinase inhibitor
WO2020123800A1
Crystalline forms and salt forms of a kinase inhibitor
BR112020021269A2
ANTI-ROR ANTIBODY CONSTRUCTIONS
US2021032263A1
Compounds for the Treatment of Kinase-Dependent Disorders
AU2019212719A1
Compounds for the treatment of kinase-dependent disorders
SG11202006921PA
Compounds for the treatment of kinase-dependent disorders
US2019262330A1
Method of Treating Hepatocellular Carcinoma Using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioate
AU2018279834A1
Liquid dosage forms to treat cancer
AU2018272088A1
Crystalline solid forms of salts of N-{4-[(6,7-dimethoxyquinolin-4-yl) oxy]phenyl}-N'-(4-fluorphenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use
US2019352403A1
Combinations of Cabozantinib and Atezolizumab to Treat Cancer
CA3021445A1
Triple negative breast cancer treatment method
CN109069499A
Use N- (4- (6,7- dimethoxy-quinoline -4- base oxygroup) phenyl)-N '-(4- fluorophenyl) cyclopropane -1,1- diformamide, the method for (2S)-hydroxysuccinic acid salts for treating clear-cell carcinoma
WO2017004609A1
Thiadiazole modulators of s1p and methods of making and using
WO2017004610A1
Tercyclic s1p3-sparing, s1p1 receptor agonists
WO2017004608A1
Oxadiazole modulators of s1p methods of making and using
AR105483A1
CRYSTAL FUMARATE SALT OF (S) - [3,4-DIFLUORO-2- (2-FLUORO-4-IODOPHENYLAMINE) PHENYL] [3-HIDROXI-3- (PIPERIDIN-2-IL) AZETIDIN-1-IL] - METANONE
AU2015255183A1
Azetidines as MEK inhibitors for the treatment of proliferative diseases
